Please assess the completion status of the following clinical trial:

Trial Title: CleanUP IPF for the Pulmonary Trials Cooperative

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 40 years of age~2. Diagnosed with idiopathic pulmonary fibrosis (IPF) by enrolling investigator~3. Signed informed consent~Exclusion Criteria:~1. Received antimicrobial therapy in the past 30 days~2. Contraindicated for antibiotic therapy, including but not exclusive to:~   1. Allergy or intolerance to both tetracyclines AND trimethoprim, sulfonamides or their combination~  2. Allergy or intolerance to tetracyclines AND known potassium level \> 5 mEq/L in the past 90 days.~      * If the enrolling physician feels the potassium level has normalized, documentation to that effect must be provided.~  3. Allergy or intolerance to tetracyclines AND concomitant use of angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), potassium sparing diuretic, dofetilide, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide~  4. Allergy or intolerance to tetracyclines AND known glucose-6-phosphate dehydrogenase deficiency~  5. Allergy or intolerance to tetracyclines AND untreated folate or B12 deficiency~  6. Allergy or intolerance to tetracyclines AND known renal insufficiency (defined as a glomerular filtration rate (GFR) \< 30 ml within the previous 90 days)~      * If the enrolling physician feels the renal dysfunction has resolved, documentation to that effect must be provided.~3. Pregnant or anticipate becoming pregnant~4. Use of an investigational study agent for IPF therapy within the past 30 days, or an IV infusion with a half-life of four (4) weeks.~5. Concomitant immunosuppression with azathioprine, mycophenolate, cyclophosphamide, or cyclosporine.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Antimicrobial therapy (Type: EXPERIMENTAL): Co-trimoxazole OR doxycycline
- Standard of care (Type: OTHER): Standard of care for patients with IPF for comparison

Based on this trial design, predict the completion outcome and termination type (if applicable).